8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Apr 6, 2026·SEC
Inovio Pharmaceuticals, Inc.(INO)Earnings, Financials & Key Ratios
INO•NASDAQ
Price updated Jun 19, 2026
AboutInovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.Show more
- Revenue$65K-70.0%
- EBITDA-$84M+23.3%
- Net Income-$85M+20.8%
- EPS (Diluted)-1.81+54.2%
- Gross Margin100%
- EBITDA Margin-128297.25%-155.7%
- Operating Margin-132871.32%-157.4%
- Net Margin-130000%-163.9%
- ROE-183.47%-59.0%
INO Key Insights
Inovio Pharmaceuticals, Inc. (INO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 0/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Sales declining 61.2% over 5 years
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when INO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INO Price & Volume
Inovio Pharmaceuticals, Inc. (INO) stock price & volume — 10-year historical chart
Loading chart...
INO Growth Metrics
Inovio Pharmaceuticals, Inc. (INO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-47.43%
5 Years-61.18%
3 Years-81.47%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.89%
Return on Capital
10 Years-82%
5 Years-97.63%
3 Years-114.92%
Last Year-160.02%
INO Recent Earnings
Inovio Pharmaceuticals, Inc. (INO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 3/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.28+6.7%
$0.30
Rev
—
$333,333
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.31+183.8%
$0.37
Rev
—
$333,330
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.44+13.7%
$0.51
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.61+3.2%
$0.63
Rev
—
$10,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.28vs $0.30+6.7% | —vs $333,333 |
| Q2 2026 | Mar 12, 2026 | $0.31vs $0.37+183.8% | —vs $333,330 |
| Q4 2025 | Nov 10, 2025 | $0.44vs $0.51+13.7% | — |
| Q3 2025 | Aug 12, 2025 | $0.61vs $0.63+3.2% | —vs $10,000 |
Based on last 12 quarters of dataView full earnings history →
INO Peer Comparison
Inovio Pharmaceuticals, Inc. (INO) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 OCGN | 419.77M | 1.24 | -5.39 | 8.83% | -16.05% | -1279.88% | ||
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 VXRT | 133.33M | 0.55 | 7.87 | 7.27% | 14.51% | 61.43% | 0.10 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BNTX | 22.98B | 90.89 | -17.51 | 0.2% | -39.6% | -6.03% | 0.01 |
Compare INO vs Peers
Inovio Pharmaceuticals, Inc. (INO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INO Income Statement
Inovio Pharmaceuticals, Inc. (INO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 42.22M | 30.48M | 4.11M | 7.41M | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K | 0 |
Revenue Growth % | 19.37% | -27.8% | -86.51% | 80.24% | -76.05% | 478.23% | -91.89% | -73.83% | -69.99% | -100% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.24M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 42.22M▲ 0% | 30.48M▼ 27.8% | 4.11M▼ 86.5% | 7.41M▲ 80.2% | 1.77M▼ 76.1% | 10.26M▲ 478.2% | 832.01K▼ 91.9% | 217.76K▼ 73.8% | 65.34K▼ 70.0% | -2.24M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - |
Gross Profit Growth % | 19.37% | -27.8% | -86.51% | 80.24% | -76.05% | 478.23% | -91.89% | -73.83% | -69.99% | - |
Operating Expenses | 126.86M | 124.57M | 115.22M | 131.49M | 302.99M | 277.84M | 144.77M | 112.62M | 86.89M | 81.48M |
OpEx % of Revenue | 300.48% | 408.68% | 2802.1% | 1774.25% | 17072.34% | 2707.35% | 17400.28% | 51716.91% | 132971.32% | - |
Selling, General & Admin | 28.29M | 29.32M | 27.2M | 37.25M | 53.75M | 90.19M | 47.58M | 37M | 32.68M | 16.46B |
SG&A % of Revenue | 67.01% | 96.17% | 661.57% | 502.59% | 3028.71% | 878.8% | 5718.93% | 16989.81% | 50013.89% | - |
Research & Development | 98.57M | 95.26M | 88.02M | 94.25M | 249.24M | 187.65M | 86.68M | 75.62M | 54.21M | 51.51M |
R&D % of Revenue | 233.47% | 312.51% | 2140.54% | 1271.66% | 14043.62% | 1828.55% | 10417.73% | 34727.1% | 82957.43% | - |
Other Operating Expenses | 806.82K | 360.8K | 0 | 0 | 0 | 0 | 10.51M | 0 | 0 | -2.75M |
Operating Income | -83.64M▲ 0% | -94.09M▼ 12.5% | -111.11M▼ 18.1% | -124.08M▼ 11.7% | -301.22M▼ 142.8% | -267.57M▲ 11.2% | -143.94M▲ 46.2% | -112.4M▲ 21.9% | -86.82M▲ 22.8% | -83.72M▲ 0% |
Operating Margin % | -198.11% | -308.68% | -2702.1% | -1674.25% | -16972.34% | -2607.35% | -17300.28% | -51616.91% | -132871.32% | - |
Operating Income Growth % | -9.72% | -12.49% | -18.09% | -11.68% | -142.76% | 11.17% | 46.21% | 21.91% | 22.76% | - |
EBITDA | -80.17M | -89.09M | -105.59M | -119.45M | -296.49M | -262.08M | -140.44M | -109.27M | -83.83M | -80.73M |
EBITDA Margin % | -189.9% | -292.29% | -2567.95% | -1611.8% | -16705.78% | -2553.8% | -16879.18% | -50179.5% | -128297.25% | - |
EBITDA Growth % | -9.6% | -11.13% | -18.52% | -13.13% | -148.2% | 11.61% | 46.41% | 22.19% | 23.28% | 21.51% |
D&A (Non-Cash Add-back) | 3.47M | 5M | 5.52M | 4.63M | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M | 2.99M |
EBIT | -88.18M | -94.8M | -112.86M | -154.19M | -301.29M | -276.4M | -133.89M | -107.08M | -84.95M | -87.2M |
Net Interest Income | 1.81M | 2.26M | -5.34M | -5.39M | 1.43M | 3.53M | 6.91M | 4.59M | 2.42M | 553.61M |
Interest Income | 1.84M | 2.26M | 2.61M | 3.31M | 3.36M | 4.78M | 8.13M | 4.77M | 2.42M | 553.61M |
Interest Expense | 25.93K | 0 | 7.95M | 8.7M | 1.94M | 1.25M | 1.22M | 177.83K | 0 | 0 |
Other Income/Expense | -4.56M | -706.88K | -9.7M | -43.39M | -2.44M | -12.24M | 8.82M | 5.14M | 1.88M | -1.21M |
Pretax Income | -88.21M▲ 0% | -94.8M▼ 7.5% | -120.81M▼ 27.4% | -167.47M▼ 38.6% | -303.66M▼ 81.3% | -279.82M▲ 7.9% | -135.12M▲ 51.7% | -107.25M▲ 20.6% | -84.95M▲ 20.8% | -84.93M▲ 0% |
Pretax Margin % | -208.92% | -311% | -2938.01% | -2259.75% | -17109.87% | -2726.67% | -16239.87% | -49254.27% | -130000% | - |
Income Tax | 0 | 2.17M | -257.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -2.29% | 0.21% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -88.21M▲ 0% | -96.97M▼ 9.9% | -119.36M▼ 23.1% | -166.41M▼ 39.4% | -303.66M▼ 82.5% | -279.82M▲ 7.9% | -135.12M▲ 51.7% | -107.25M▲ 20.6% | -84.95M▲ 20.8% | -84.93M▲ 0% |
Net Margin % | -208.92% | -318.12% | -2902.75% | -2245.39% | -17109.87% | -2726.67% | -16239.87% | -49254.27% | -130000% | - |
Net Income Growth % | -19.62% | -9.93% | -23.09% | -39.42% | -82.47% | 7.85% | 51.71% | 20.62% | 20.8% | 11.97% |
Net Income (Continuing) | -88.21M | -96.97M | -120.55M | -167.47M | -303.66M | -279.82M | -135.12M | -107.25M | -84.95M | -84.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 96.27K | 96.27K | 1.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.08▲ 0% | -1.05▲ 2.8% | -0.97▲ 7.6% | -1.07▼ 10.3% | -1.42▼ 32.7% | -14.07▼ 890.8% | -6.09▲ 56.7% | -3.95▲ 35.1% | -1.81▲ 54.2% | -0.12▲ 0% |
EPS Growth % | -6.93% | 2.78% | 7.62% | -10.31% | -32.71% | -890.85% | 56.72% | 35.14% | 54.18% | 99.89% |
EPS (Basic) | -1.08 | -1.05 | -0.97 | -1.07 | -1.42 | -14.07 | -6.09 | -3.95 | -1.81 | - |
Diluted Shares Outstanding | 81.92M | 92.54M | 124.62M | 169.87M | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M | 691.02M |
Basic Shares Outstanding | 81.78M | 92.35M | 124.62M | 165.36M | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M | 691.02M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INO Balance Sheet
Inovio Pharmaceuticals, Inc. (INO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 138.36M | 87.81M | 94.2M | 471.17M | 448.44M | 315.24M | 153.11M | 97.83M | 61.12M | 39.44M |
Cash & Short-Term Investments | 127.43M | 81.23M | 89.53M | 411.64M | 401.31M | 253M | 145.29M | 94.11M | 58.51M | 37.68M |
Cash Only | 23.79M | 23.69M | 22.2M | 250.73M | 71.14M | 46.33M | 14.31M | 65.81M | 44.27M | 26.27M |
Short-Term Investments | 103.64M | 57.54M | 67.34M | 160.91M | 330.17M | 206.67M | 130.98M | 28.3M | 14.24M | 11.41M |
Accounts Receivable | 6.49M | 4.05M | 2.03M | 19.06M | 8.03M | 11.74M | 2.41M | 1.2M | 450 | 0 |
Days Sales Outstanding | 56.11 | 48.56 | 180.38 | 938.88 | 1.65K | 417.5 | 1.06K | 2.01K | 2.51 | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 261.19K | 30.38M | 20.43K | 0 | 0 | 0 |
Total Non-Current Assets | 48.88M | 43.3M | 49.75M | 68.6M | 47.5M | 33.29M | 17.84M | 15.37M | 13.19M | 10.34M |
Property, Plant & Equipment | 18.32M | 15.95M | 26.56M | 24.09M | 29.02M | 17.96M | 14.45M | 11.77M | 9.07M | 8.33M |
Fixed Asset Turnover | 2.30x | 1.91x | 0.15x | 0.31x | 0.06x | 0.57x | 0.06x | 0.02x | 0.01x | 0.00x |
Goodwill | 10.51M | 10.51M | 10.51M | 10.51M | 10.51M | 10.51M | 0 | 0 | 0 | 0 |
Intangible Assets | 6.01M | 4.76M | 3.69M | 3.15M | 2.63M | 2.13M | 0 | 0 | 0 | 0 |
Long-Term Investments | 11.39M | 9.41M | 6.32M | 4.89M | 3.91M | 2.01M | 2.78M | 1.61M | 2.1M | 7.68M |
Other Non-Current Assets | 2.64M | 2.67M | 2.67M | 25.96M | 1.43M | 684.04K | 605.32K | 1.98M | 2.01M | 2.01M |
Total Assets | 187.24M▲ 0% | 131.11M▼ 30.0% | 143.95M▲ 9.8% | 539.77M▲ 275.0% | 495.94M▼ 8.1% | 348.53M▼ 29.7% | 170.95M▼ 51.0% | 113.2M▼ 33.8% | 74.31M▼ 34.4% | 49.78M▲ 0% |
Asset Turnover | 0.23x | 0.23x | 0.03x | 0.01x | 0.00x | 0.03x | 0.00x | 0.00x | 0.00x | 0.00x |
Asset Growth % | 7.79% | -29.98% | 9.79% | 274.97% | -8.12% | -29.72% | -50.95% | -33.78% | -34.35% | -161.5% |
Total Current Liabilities | 35.41M | 35.3M | 31.99M | 41.71M | 65.74M | 96.87M | 42.57M | 35.33M | 43.67M | 37.92M |
Accounts Payable | 8.49M | 11.02M | 7.65M | 1.47M | 27.97M | 21.08M | 4.65M | 6.44M | 2.62M | 1.99M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - | 651.2 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 16.77M | 0 | 0 | 0 |
Deferred Revenue (Current) | 1.35M | 257.15K | 124.13K | 46.63K | 21.63K | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9.24M | 14.73M | 15.74M | 20.66M | 20.71M | 15.14M | 9.95M | 23.26M | 36.44M | 27.02M |
Current Ratio | 3.91x | 2.49x | 2.94x | 11.30x | 6.82x | 3.25x | 3.60x | 2.77x | 1.40x | 1.04x |
Quick Ratio | 3.91x | 2.49x | 2.94x | 11.30x | 6.82x | 3.25x | 3.60x | 2.77x | 1.40x | 1.04x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 9.35M | 8.78M | 106.56M | 36.93M | 30.53M | 29.3M | 11.03M | 9.37M | 6.55M | 5.79M |
Long-Term Debt | 0 | 0 | 77.02M | 18.66M | 14.96M | 16.61M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 20.41M | 18.06M | 15.46M | 12.66M | 11.03M | 9.37M | 6.55M | 27.62M |
Deferred Tax Liabilities | 24.77K | 24.77K | 32.05K | 32.05K | 32.05K | 32.05K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9.1M | 8.61M | 8.99M | 95.16K | 14.83K | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 44.75M | 44.08M | 138.55M | 78.63M | 96.27M | 126.17M | 53.6M | 44.69M | 50.21M | 43.71M |
Total Debt | 0 | 0 | 99.51M | 39.05M | 33.02M | 32.07M | 30.21M | 11.87M | 9.37M | 8.7M |
Net Debt | -23.79M | -23.69M | 77.31M | -211.68M | -38.12M | -14.25M | 15.9M | -53.95M | -34.91M | -17.58M |
Debt / Equity | - | - | 18.41x | 0.08x | 0.08x | 0.14x | 0.26x | 0.17x | 0.39x | 1.43x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.22x |
Interest Coverage | -3400.29x | - | -14.20x | -17.72x | -155.59x | -220.42x | -109.50x | -602.12x | - | - |
Total Equity | 142.49M▲ 0% | 87.03M▼ 38.9% | 5.4M▼ 93.8% | 461.14M▲ 8432.0% | 399.67M▼ 13.3% | 222.36M▼ 44.4% | 117.35M▼ 47.2% | 68.5M▼ 41.6% | 24.1M▼ 64.8% | 6.07M▲ 0% |
Equity Growth % | 15.49% | -38.92% | -93.79% | 8431.97% | -13.33% | -44.36% | -47.23% | -41.62% | -64.82% | -333.99% |
Book Value per Share | 1.74 | 0.94 | 0.04 | 2.71 | 1.86 | 11.18 | 5.29 | 2.52 | 0.05 | 0.01 |
Total Shareholders' Equity | 142.39M | 86.94M | 3.44M | 461.14M | 399.67M | 222.36M | 117.35M | 68.5M | 24.1M | 6.07M |
Common Stock | 90.36K | 97.23K | 101.36K | 186.85K | 217.38K | 21.09K | 22.79K | 36.1K | 69K | 69.77K |
Retained Earnings | -523.36M | -620.43M | -739.79M | -906.2M | -1.21B | -1.49B | -1.62B | -1.73B | -1.82B | -1.83B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -117K | -528.87K | 472.61K | -256.15K | -282.24K | -698.74K | -662.6K | -675.67K | -637.96K | -636.09K |
Minority Interest | 96.27K | 96.27K | 1.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INO Cash Flow Statement
Inovio Pharmaceuticals, Inc. (INO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -63.21M | -73.55M | -97.85M | -177.98M | -215.71M | -216.22M | -124.37M | -104.08M | -88.63M | -83.35M |
Operating CF Margin % | -149.71% | -241.29% | -2379.66% | -2401.48% | -12154.25% | -2106.9% | -14947.6% | -47795.03% | -135637.22% | - |
Operating CF Growth % | -1.05% | -16.36% | -33.04% | -81.89% | -21.2% | -0.24% | 42.48% | 16.31% | 14.84% | 68.76% |
Net Income | -88.21M | -96.97M | -120.55M | -167.47M | -303.66M | -279.82M | -135.12M | -107.25M | -84.95M | -84.93M |
Depreciation & Amortization | 3.47M | 5M | 5.52M | 4.63M | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M | 2.99M |
Stock-Based Compensation | 13.07M | 10.65M | 10.9M | 15.65M | 26.34M | 22.56M | 11.07M | 6.6M | 3.76M | 2.36M |
Deferred Taxes | -150.03K | 3.42M | -260.82K | 37.93M | 0 | 4.03M | -32.05K | 0 | 0 | 0 |
Other Non-Cash Items | 5.71M | -360.8K | 10.09M | 2.36M | 6.53M | 11.69M | 6.47M | -3.88M | -1.21M | 2.2M |
Working Capital Changes | 2.9M | 4.71M | -3.54M | -71.07M | 50.35M | 19.83M | -10.26M | -2.66M | -9.22M | -5.96M |
Change in Receivables | 10.08M | 2.43M | 2.02M | -17.02M | 11.03M | -3.71M | 9.33M | 1.21M | 0 | 331.65K |
Change in Inventory | 531.87K | -963.92K | 935.79K | -55.15M | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 2.68M | 601.26K | -4.59M | 3.25M | 26.14M | 32.61M | -45.99M | -3.37M | -6.42M | -4.12M |
Cash from Investing | -27.83M | 42.42M | -9.04M | -58.8M | -175.34M | 109.59M | 87.36M | 104.07M | 14.04M | 16.73M |
Capital Expenditures | -10.29M | -2.09M | -987.93K | -1.52M | -1.23M | -969.15K | -320.9K | -487.83K | -285.7K | -226.32K |
CapEx % of Revenue | 24.38% | 6.84% | 24.03% | 20.52% | 69.36% | 9.44% | 38.57% | 224.03% | 437.23% | - |
Acquisitions | 0 | 2.78T | 987.93B | 38.73M | 0 | -2M | 6.22M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 1M | -2.78T | -987.93B | -2.77M | 0 | 0 | 0 | 59.32K | 0 | 0 |
Cash from Financing | 95.69M | 31.04M | 105.4M | 465.28M | 211.5M | 81.84M | 5M | 51.48M | 53.05M | 52.98M |
Debt Issued (Net) | 0 | 0 | 97.44M | 171.62K | 0 | 0 | 0 | -16.41M | 0 | 0 |
Equity Issued (Net) | 94.35M | 29.23M | 9.09M | 454.49M | 209.44M | 82.96M | 5.46M | 68.31M | 53.16M | 53.14M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.34M | 1.81M | -1.14M | 10.62M | 2.06M | -1.11M | -466.65K | -420.8K | -110.78K | -166.8K |
Net Change in Cash | 4.65M▲ 0% | -92.95K▼ 102.0% | -1.5M▼ 1511.2% | 228.53M▲ 15360.5% | -179.58M▼ 178.6% | -24.81M▲ 86.2% | -32.02M▼ 29.0% | 51.5M▲ 260.9% | -21.54M▼ 141.8% | -13.64M▲ 0% |
Free Cash Flow | -73.5M▲ 0% | -75.64M▼ 2.9% | -98.84M▼ 30.7% | -179.5M▼ 81.6% | -216.94M▼ 20.9% | -217.18M▼ 0.1% | -124.69M▲ 42.6% | -104.56M▲ 16.1% | -88.92M▲ 15.0% | -83.57M▲ 0% |
FCF Margin % | -174.09% | -248.13% | -2403.69% | -2422% | -12223.61% | -2116.34% | -14986.17% | -48019.06% | -136074.45% | - |
FCF Growth % | -10.54% | -2.9% | -30.68% | -81.61% | -20.86% | -0.11% | 42.59% | 16.14% | 14.97% | 18.63% |
FCF per Share | -0.90 | -0.82 | -0.79 | -1.06 | -1.01 | -10.92 | -5.62 | -3.85 | -0.19 | -0.12 |
FCF Conversion (FCF/Net Income) | 0.72x | 0.76x | 0.82x | 1.07x | 0.71x | 0.77x | 0.92x | 0.97x | 1.04x | 0.98x |
Interest Paid | 0 | 0 | 0 | 4.62M | 1.08M | 1.07M | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 2.72M | 4.62M | 1.08M | 1.07M | 0 | 0 | 0 | 66.69K |
INO Key Ratios
Inovio Pharmaceuticals, Inc. (INO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -66.35% | -84.5% | -258.25% | -71.34% | -70.55% | -89.97% | -79.55% | -115.42% | -183.47% | -666.47% |
Return on Invested Capital (ROIC) | -56.28% | -77.53% | -114.11% | -56.03% | -73.95% | -70.46% | -63.25% | -114.07% | -3476.16% | 601.63% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - |
Net Margin | -208.92% | -318.12% | -2902.75% | -2245.39% | -17109.87% | -2726.67% | -16239.87% | -49254.27% | -130000% | - |
Debt / Equity | - | - | 18.41x | 0.08x | 0.08x | 0.14x | 0.26x | 0.17x | 0.39x | 1.43x |
Interest Coverage | -3400.29x | - | -14.20x | -17.72x | -155.59x | -220.42x | -109.50x | -602.12x | - | - |
FCF Conversion | 0.72x | 0.76x | 0.82x | 1.07x | 0.71x | 0.77x | 0.92x | 0.97x | 1.04x | 0.98x |
Revenue Growth | 19.37% | -27.8% | -86.51% | 80.24% | -76.05% | 478.23% | -91.89% | -73.83% | -69.99% | -100% |
Related:INO Dividend History·INO Revenue History·INO Price History·INO P/E History·INO Financial Ratios·INO Institutional Holders
INO SEC Filings & Documents
Inovio Pharmaceuticals, Inc. (INO) SEC filings — annual & quarterly reports (10-K, 10-Q)
INO Frequently Asked Questions
Inovio Pharmaceuticals, Inc. (INO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Inovio Pharmaceuticals, Inc. (INO) reported $0.1M in revenue for fiscal year 2025. This represents a 99% decrease from $8.3M in 1999.
Inovio Pharmaceuticals, Inc. (INO) saw revenue decline by 70.0% over the past year.
Inovio Pharmaceuticals, Inc. (INO) reported a net loss of $84.9M for fiscal year 2025.
Dividend & Returns
Inovio Pharmaceuticals, Inc. (INO) has a return on equity (ROE) of -183.5%. Negative ROE indicates the company is unprofitable.
Inovio Pharmaceuticals, Inc. (INO) had negative free cash flow of $83.6M in fiscal year 2025, likely due to heavy capital investments.